{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:34:28Z","timestamp":1788975268811,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bbmt.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T02:16:36Z","timestamp":1557540996000},"page":"1792-1797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma"],"prefix":"10.1016","volume":"25","author":[{"given":"El\u017cbieta","family":"Wawrzyniak-Dzier\u017cek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Gajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ryczan-Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"W\u0119c\u0142awek-Tompol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Raciborska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Mielcarek-Siedziuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jowita","family":"Fr\u0105czkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Salamonowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Ka\u0142wak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u015al\u0119zak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ussowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.05.006_bib0001","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/bmt.2012.284","article-title":"Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience","volume":"48","author":"Hale","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0002","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0003","first-page":"369","article-title":"High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors","volume":"8","author":"Saarinen","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00043426-199801000-00008","article-title":"Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I\/II study of the Pediatric Blood and Marrow Transplant Consortium","volume":"20","author":"Kletzel","year":"1998","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bmt.1701283","article-title":"Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors","volume":"22","author":"Hara","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0006","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.bmt.1701395","article-title":"Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors","volume":"22","author":"Lucidarme","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0007","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bmt.1703213","article-title":"Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults","volume":"28","author":"Kushner","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0008","first-page":"5527","article-title":"Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma","volume":"32","author":"De Ioris","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0009","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.cad.0000215059.93437.89","article-title":"Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines","volume":"17","author":"Lanvers-Kaminsky","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0010","first-page":"101","article-title":"Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant","volume":"117","author":"Raciborska","year":"2015","journal-title":"Klin Oczna"},{"issue":"3Pt 1","key":"10.1016\/j.bbmt.2019.05.006_bib0011","first-page":"775","article-title":"[High-dose therapy followed by auto HSCT in children with advanced neuroblastoma in four transplant centres in Poland]","volume":"10","author":"Zaucha-Prazmo","year":"2006","journal-title":"Med Wieku Rozwoj"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0012","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2005.03.004","article-title":"Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells","volume":"33","author":"Bitan","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0013","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1200\/JCO.2006.06.7272","article-title":"Irinotecanplus temozolomide for relapsed or refractory neuroblastoma","volume":"24","author":"Kushner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0014","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 5.0. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed July 17, 2018."},{"key":"10.1016\/j.bbmt.2019.05.006_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society For Blood And Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1399-3046.2006.00589.x","article-title":"Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate","volume":"10","author":"Termuhlen","year":"2006","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0017","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pbc.24173","article-title":"Thiotepa and melphalan-based single, tandem, and triple high-dose therapy and autologous stem cell transplantation for high-risk neuroblastoma","volume":"59","author":"Saarinen-Pihkala","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2015.264","article-title":"Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients","volume":"51","author":"Pasqualini","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"18 Suppl","key":"10.1016\/j.bbmt.2019.05.006_bib0019","article-title":"A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): a Children's Oncology Group (COG) study","volume":"34","author":"Park","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0020","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1200\/JCO.2006.05.6986","article-title":"High-risk neuroblastoma treated with tandem autologous peripheral blood stem cell-supported transplantation: long-term survival update","volume":"24","author":"George","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/bmt.2012.86","article-title":"Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study","volume":"48","author":"Sung","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-017-0477-0","article-title":"Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study","volume":"10","author":"Lee","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0023","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/pbc.25169","article-title":"The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms","volume":"61","author":"Willems","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pbc.21955","article-title":"KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors","volume":"53","author":"P\u00e9rez-Mart\u00ednez","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0025","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","article-title":"Genotypes of NK cell KIR receptors, their ligands, and Fc\u03b3 receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy","volume":"70","author":"Delgado","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0026","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-17-1767","article-title":"Neuroblastoma patients\u2019 KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children's Oncology Group","volume":"24","author":"Erbe","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0027","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.bbmt.2009.05.007","article-title":"High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed\/refractory neuroblastoma","volume":"15","author":"Toporski","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0028","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2017.12.805","article-title":"Haploidentical stem cell transplantation for refractory\/relapsed neuroblastoma","volume":"24","author":"Illhardt","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0029","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/cncr.30934","article-title":"Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials","volume":"123","author":"London","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0030","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/bmt.2015.71","article-title":"Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF","volume":"50","author":"Maschan","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.006_bib0031","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/trf.13599","article-title":"Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients","volume":"56","author":"Teusink","year":"2016","journal-title":"Transfusion"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119302903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119302903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:07:18Z","timestamp":1761059238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119302903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1083879119302903"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.006","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}